Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts.
Peter MartinJonathon B CohenMichael L WangAnita KumarBrian HillDiego R VillaJeffrey M SwitchenkoBrad S KahlKami MaddocksNatalie Sophia GroverKeqin QiLori ParisiKatherine DalyAngeline ZhuGilles Andre SallesPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
In this large cohort of patients treated primarily in the US community setting, only one in four young patients received cytarabine or ASCT consolidation, suggesting the need to develop treatments that can be delivered effectively in routine clinical practice. Together with the validation cohort, data support future clinical trials exploring regimens without ASCT consolidation in young patients, whereas MR should be considered for patients after 1L BR and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Keyphrases
- end stage renal disease
- ejection fraction
- clinical trial
- newly diagnosed
- chronic kidney disease
- clinical practice
- peritoneal dialysis
- prognostic factors
- healthcare
- stem cells
- magnetic resonance imaging
- randomized controlled trial
- magnetic resonance
- computed tomography
- mental health
- diffuse large b cell lymphoma
- drug delivery
- electronic health record
- deep learning
- mesenchymal stem cells
- big data
- cancer therapy
- current status
- phase ii